

Tove Wsterlid

List of Publications by Citations

Source: <https://exaly.com/author-pdf/4445420/tove-wasterlid-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

23
papers

145
citations

6
h-index

12
g-index

26
ext. papers

187
ext. citations

3.8
avg, IF

2.69
L-index

#	Paper	IF	Citations
23	Impact of chemotherapy regimen and rituximab in adult Burkitt lymphoma: a retrospective population-based study from the Nordic Lymphoma Group. <i>Annals of Oncology</i> , 2013 , 24, 1879-1886	10.3	54
22	Population based study of prognostic factors and treatment in adult Burkitt lymphoma: a Swedish Lymphoma Registry study. <i>Leukemia and Lymphoma</i> , 2011 , 52, 2090-6	1.9	21
21	Impact of comorbidity on disease characteristics, treatment intent and outcome in diffuse large B-cell lymphoma: a Swedish lymphoma register study. <i>Journal of Internal Medicine</i> , 2019 , 285, 455-468	10.8	19
20	Statin use is associated with improved survival in multiple myeloma: A Swedish population-based study of 4315 patients. <i>American Journal of Hematology</i> , 2020 , 95, 652-661	7.1	11
19	Impact on survival of addition of etoposide to primary chemotherapy in diffuse large B-cell lymphoma: a Swedish Lymphoma Registry study. <i>Hematological Oncology</i> , 2017 , 35, 151-157	1.3	9
18	Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real-world patients. <i>British Journal of Haematology</i> , 2020 , 189, 661-671	4.5	8
17	Six cycles of R-CHOP-21 are not inferior to eight cycles for treatment of diffuse large B-cell lymphoma: a Nordic Lymphoma Group Population-based Study. <i>Annals of Oncology</i> , 2018 , 29, 1882-1883	10.3	6
16	Outcome and determinants of failure to complete primary R-CHOP treatment for reasons other than non-response among patients with diffuse large B-cell lymphoma. <i>American Journal of Hematology</i> , 2020 , 95, 740-748	7.1	5
15	Survival of very elderly patients with diffuse large B-cell lymphoma according to treatment intensity in the immunochemotherapy era: a Swedish Lymphoma Register study. <i>British Journal of Haematology</i> , 2021 , 192, 75-81	4.5	4
14	Clinical characteristics and outcomes among 2347 patients aged 85 years with major lymphoma subtypes: a Nordic Lymphoma Group study. <i>British Journal of Haematology</i> , 2021 , 192, 551-559	4.5	4
13	Frequency and clinical implications of SOX11 expression in Burkitt lymphoma. <i>Leukemia and Lymphoma</i> , 2017 , 58, 1760-1763	1.9	1
12	Real-world data on treatment and outcomes of patients with primary mediastinal large B-cell lymphoma: a Swedish lymphoma register study. <i>Blood Cancer Journal</i> , 2021 , 11, 100	7	1
11	Statin use and survival in 16 098 patients with non-Hodgkin lymphoma or chronic lymphocytic leukaemia treated in the rituximab era. <i>British Journal of Haematology</i> , 2021 , 195, 552-560	4.5	1
10	Application of precision medicine in clinical routine in haematology: Challenges and opportunities. <i>Journal of Internal Medicine</i> ,	10.8	1
9	Temporary cessation of ibrutinib results in reduced grade 3-4 infections and durable remissions: Interim analysis of an on-off-repeat Phase 1b/2 study in patients with chronic lymphocytic leukemia. <i>EJHaem</i> , 2021 , 2, 525-529	0.9	0
8	Sex Differences in Lymphoma Incidence and Excess Mortality By Subtype: A Comprehensive National Study. <i>Blood</i> , 2021 , 138, 2534-2534	2.2	
7	Good Outcome after R-Hyper-CVAD/R-MA in High-Risk Aggressive B-Cell Lymphoma: A Single-Center Experience. <i>Blood</i> , 2021 , 138, 4587-4587	2.2	

- 6 Clinical Characteristics and Outcomes Among Very Elderly Patients with Major Lymphoma Subtypes: A Nordic Lymphoma Group Study. *Blood*, **2018**, 132, 571-571 2.2
- 5 Normalization of Survival and No Relapses after One Year in Adult Burkitt Lymphoma Patients Treated with Intensive Immunochemotherapy: An International Study of 159 Real-World Patients. *Blood*, **2018**, 132, 452-452 2.2
- 4 Inferior Outcomes for Older Patients in the Adolescent and Young Adult (AYA) Population with Burkitt Lymphoma Treated with Intensive Immunochemotherapy: An International Study of 108 Patients. *Blood*, **2019**, 134, 4113-4113 2.2
- 3 Encouraging Outcomes with Intensive Chemotherapy for Patients with Primary Mediastinal B-Cell Lymphoma - a Swedish Lymphoma Register Study. *Blood*, **2019**, 134, 1618-1618 2.2
- 2 R-CHOEP-14 Is Associated with Superior Overall Survival Compared to R-CHOP-21 and R-CHOP-14 in Patients with DLBCL \geq 70 Years in a Swedish Lymphoma Registry Population Based Study. *Blood*, **2014**, 124, 4427-4427 2.2
- 1 Frequency and Clinical Implication of SOX11 Expression in Burkitt Lymphoma. *Blood*, **2015**, 126, 5039-5039 2.2